Targeted Therapies in BRAF-Mutant Melanoma

The identification of activating mutations in the BRAF kinase, most notably the V600E substitution, has transformed the therapeutic landscape of advanced melanoma. Approximately half of melanomas harbour these mutations, which drive oncogenic signalling through the MAPK pathway. The clinical deployment of selective BRAF inhibitors, alone or in combination with MEK inhibitors, has yielded rapid tumour regressions, significant extensions in progression-free survival and measurable gains in overall survival. However, therapeutic resistance—whether intrinsic or acquired—remains a formidable barrier, often arising through pathway reactivation or bypass mechanisms. To address this, combination regimens have been refined to include dual BRAF/MEK blockade, sequential or concomitant integration with immune-checkpoint inhibitors and exploration of novel small-molecule or antibody agents targeting resistance nodes. Ongoing efforts focus on optimising treatment sequencing, minimising toxicity and developing predictive biomarkers. Collectively, these advances underscore the global significance of precision oncology in melanoma and pave the way for more durable and personalised management strategies.

Research from Nature Portfolio

Recent studies have evaluated optimal sequencing of immunotherapy and targeted therapy in patients with BRAF V600-mutant melanoma. A randomised phase II trial compared frontline dual checkpoint blockade followed by BRAF/MEK inhibition to the reverse sequence and an induction-switch strategy. Four-year follow-up demonstrated that initial immunotherapy delivered the greatest long-term survival benefit, while subsequent targeted therapy maintained disease control. Parallel biomarker analyses identified loss-of-function alterations in JAK signalling and low baseline interferon-gamma levels as candidate predictors of durable responses across both treatment modalities. These findings refine our understanding of how to integrate targeted agents with immunomodulatory approaches and highlight molecular features that may guide personalised sequencing decisions.

Targeted Therapies in BRAF-Mutant Melanoma publication trend

The graph below shows the total number of articles in targeted therapies in braf-mutant melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

BRAF V600 mutation: A substitution of valine by glutamic acid at residue 600 of the BRAF kinase, leading to constitutive activation of the MAPK pathway.

MEK inhibitor: A drug that selectively blocks the MEK1/2 kinases downstream of BRAF, interrupting MAPK signalling.

Checkpoint inhibitor: An antibody that blocks immune-regulatory receptors such as PD-1 or CTLA-4 to enhance antitumour T-cell activity.

Progression-free survival: The interval during which a patient’s disease does not worsen after initiation of therapy.

Patient-derived xenograft (PDX): A preclinical model in which human tumour tissue is implanted into a host organism to study therapeutic responses.

Biomarker: A measurable molecular or cellular indicator used to predict response to a specific therapy or to monitor disease status.

References

1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications (2024).
2. An in vivo avian model of human melanoma to perform rapid and robust preclinical studies. EMBO Molecular Medicine (2023).
3. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (2020).
4. Systemic Therapy of Metastatic Melanoma: On the Road to Cure. Cancers (2021).